Onco-Innovations Plans Nasdaq Cross-listing and Possible Equity Offering

Onco-Innovations Limited, a Vancouver-based company, has engaged a U.S. investment bank to act as its advisor. This move aligns with the company's plans to cross-list its common shares on the Nasdaq Stock Market and consider a concurrent equity financing. The specifics of the financing are yet to be determined.

This initiative is part of Onco-Innovations' broader strategy to explore options for sustained corporate growth. The advisory role includes planning around listing requirements, regulatory factors, and capital strategies necessary for the potential cross-listing and financing.

However, the company cautions that there are no guarantees of completion as the plans are subject to regulatory and exchange requirements. Onco-Innovations remains focused on cancer research and treatment innovations.